Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.

  • Authors:
    • J A Ellerhorst
    • A Bedikian
    • S Ring
    • A C Buzaid
    • O Eton
    • S S Legha
  • View Affiliations

  • Published online on: September 1, 1999     https://doi.org/10.3892/or.6.5.1097
  • Pages: 1097-1106
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Treatment options for patients with stage IV melanoma are limited. Based on differences in the toxicity and activity profiles of pegylated liposomal doxorubicin (doxil) compared to standard doxorubicin, we have conducted a phase II trial of doxil for patients with metastatic melanoma. Doxil was administered as a 60-90 min intravenous infusion every 21 days. The starting dose was 60 mg/m2 for the initial nine patients, but was subsequently reduced to 50 mg/m2 for the remainder due to toxicity issues. Thirty-two patients were enrolled in the trial. Ninety-one percent had received prior systemic therapy. There were no complete responses and two partial responses for an overall response rate of 6%. The dominant side effects included hand-foot syndrome, rash (occasionally severe), and stomatitis, consistent with reports from other trials using similar doses and schedules. We conclude that doxil does not demonstrate sufficient activity in metastatic melanoma to warrant further investigation into its use in this setting.

Related Articles

Journal Cover

Sep-Oct 1999
Volume 6 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ellerhorst J, Bedikian A, Ring S, Buzaid A, Eton O and Legha S: Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.. Oncol Rep 6: 1097-1106, 1999.
APA
Ellerhorst, J., Bedikian, A., Ring, S., Buzaid, A., Eton, O., & Legha, S. (1999). Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.. Oncology Reports, 6, 1097-1106. https://doi.org/10.3892/or.6.5.1097
MLA
Ellerhorst, J., Bedikian, A., Ring, S., Buzaid, A., Eton, O., Legha, S."Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.". Oncology Reports 6.5 (1999): 1097-1106.
Chicago
Ellerhorst, J., Bedikian, A., Ring, S., Buzaid, A., Eton, O., Legha, S."Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.". Oncology Reports 6, no. 5 (1999): 1097-1106. https://doi.org/10.3892/or.6.5.1097